Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederjnj.com
RSS Feed ALL
Get the latest updates from RSS Feed ALL directly as they happen.
Follow now 194 followers
Latest posts
Last updated about 10 hours ago
Johnson & Johnson Continues U.S. Investment with $2 Billion Commitment to Enable Manufacturing at State-Of-The-Art North Carolina Facility
8 days ago
• Company increases presence in North Carolina with a 160,000+ square foot...
Johnson & Johnson to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
29 days ago
Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis
about 1 month ago
Submission is supported by 24-week results from the Phase 3b APEX study...
Johnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions
about 1 month ago
Early VIRTUGUIDE™ surgeons report a 30-minute reduction in surgical time versus traditional...
Johnson & Johnson showcases latest advancements in Alzheimer’s research at AAIC 2025
about 1 month ago
Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company’s leadership...
European Commission approves DARZALEX® (daratumumab) as the first licensed treatment for patients with high-risk smouldering multiple myeloma
about 1 month ago
Landmark approval is based on results from the Phase 3 AQUILA study...
European Commission approves IMBRUVICA® (ibrutinib) as the first targeted therapy for patients with previously untreated mantle cell lymphoma who would be eligible for autologous stem cell transplant
about 1 month ago
Ibrutinib is the first approved Bruton’s tyrosine kinase (BTK) inhibitor to demonstrate...
Johnson & Johnson Announces Strategic Agreement with Pacira BioSciences to Expand Early Intervention Offering for Osteoarthritis of the Knee
about 1 month ago
Agreement enhances the Early Intervention portfolio to tackle the increasing burden of...
Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis
about 1 month ago
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the...